• Policy
• CSO expenditure report Act, effective immediately
• by Lee, Jeong-Hwan Jul 20, 2021 05:47am

• Policy
• Kymriah reimbursement was not discussed at CDRC meeting
• by Lee, Jeong-Hwan Jul 20, 2021 05:47am

• Policy
• Pfizer vaccine available in Korea for ages 12 or older
• by Lee, Tak-Sun Jul 20, 2021 05:46am

• Company
• The Effects and Challenges of Vitrakvi
• by Jul 20, 2021 05:46am

• Company
• ‘Tagrisso’ tenaciously attempts reimb. for 1st line NSCLC
• by Eo, Yun-Ho Jul 19, 2021 10:34am

• Company
• Prolonged Galvus patent dispute… results to come next year?
• by Kim, Jin-Gu Jul 19, 2021 05:56am

• Company
• Emtuen became the largest shareholder of SillaJen
• by An, Kyung-Jin Jul 19, 2021 05:56am

• Company
• ↑38% of drug exports in the first half
• by Kim, Jin-Gu Jul 19, 2021 05:56am

• Policy
• Aduhel has been applied for permission in Korea
• by Lee, Tak-Sun Jul 19, 2021 05:56am

• Company
• Onivyde is expected to be eligible for insurance coverage
• by Eo, Yun-Ho Jul 16, 2021 05:54am